



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	1	of	4
Application Number	12/098,577		
Filing Date	April 7, 2008		
First Named Inventor	BUSSE, Ursula		
Art Unit	1645		
Examiner Name	To Be Assigned		
Attorney Docket Number	1619.0080002/JAG/CMB		

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>3</sup> (if Known)			
	US1	4,581,333	12/08/1986	Kourilsky <i>et al.</i>	
	US2	4,683,195	07/28/1987	Mullis <i>et al.</i>	
	US3	4,683,202	07/28/1987	Mullis	
	US4	4,786,600	11/22/1988	Kramer <i>et al.</i>	
	US5	4,800,159	01/24/1989	Mullis <i>et al.</i>	
	US6	4,965,188	10/23/1990	Mullis <i>et al.</i>	
	US7	5,002,867	03/26/1991	Macevicz	
	US8	5,068,176	11/26/1991	Vijg <i>et al.</i>	
	US9	5,112,736	05/12/1992	Caldwell <i>et al.</i>	
	US10	5,118,801	06/02/1992	Lizardi	
	US11	5,149,625	09/22/1992	Church <i>et al.</i>	
	US12	5,202,231	12/13/1993	Drmanac <i>et al.</i>	
	US13	5,219,989	06/15/1993	Sonenberg <i>et al.</i>	
	US14	5,283,174	02/01/1994	Arnold, Jr., <i>et al.</i>	
	US15	5,312,728	05/17/1994	Lizardi <i>et al.</i>	
	US16	5,399,491	03/21/1995	Kaclan <i>et al.</i>	
	US17	5,422,252	06/06/1995	Walker <i>et al.</i>	
	US18	5,466,590	11/14/1995	Sariaslani <i>et al.</i>	
	US19	5,503,980	04/02/1996	Cantor	
	US20	5,547,842	08/20/1996	Hogan <i>et al.</i>	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	FP1	EP 0 160 228	11/06/1985	Cetus Corp.		
	FP2	EP 0 320 308	06/14/1989	Biotechnica International Inc.		
	FP3	EP 0 520 794	12/30/1992	Hoffman La Roche, <i>et al.</i>		
	FP4	WO 93/08845	05/13/1993	Massachusetts Institute of Technology		
	FP5	WO 93/13121	07/08/1993	Isis Pharmaceuticals, Inc.		
	FP6	WO 94/09820	05/11/1994	Sloan-Kettering Institute for Cancer Research		
	FP7	WO 94/15646	07/21/1994	Thomas Jefferson University		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	2	of	4	Attorney Docket Number	1619.0080002/JAG/CMB

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If Known)			
	US21	5,554,516	09/10/1996	Kaclan <i>et al.</i>	
	US22	5,585,481	12/17/1996	Arnold, Jr., <i>et al.</i>	
	US23	5,593,974	01/14/1997	Rosenberg <i>et al.</i>	
	US24	5,639,604	06/17/1997	Arnold, Jr., <i>et al.</i>	
	US25	5,656,207	08/12/1997	Woodhead <i>et al.</i>	
	US26	5,658,737	08/19/1997	Nelson <i>et al.</i>	
	US27	5,674,682	10/07/1997	Croce <i>et al.</i>	
	US28	5,773,705	06/30/1998	Vierstra <i>et al.</i>	
	US29	5,837,832	11/17/1998	Chee <i>et al.</i>	
	US30	5,861,242	01/19/1999	Chee <i>et al.</i>	
	US31	5,925,517	07/20/1999	Tyagi <i>et al.</i>	
	US32	5,939,258	08/01/1999	Croce <i>et al.</i>	
	US33	6,037,130	03/14/2000	Tyagi <i>et al.</i>	
	US34	6,087,133	07/11/2000	Dattagupta <i>et al.</i>	
	US35	6,110,678	08/29/2000	Weisburg <i>et al.</i>	
	US36	6,261,562	07/17/2001	Xu <i>et al.</i>	
	US37	6,262,245	07/17/2001	Xu <i>et al.</i>	
	US38	6,280,952	08/28/2001	Weisburg <i>et al.</i>	
	US39	6,287,820	09/11/2001	Umansky <i>et al.</i>	
	US40	6,383,739	05/07/2002	Kurth <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	FP8	WO 95/28498	10/26/1995	The Trustees of Columbia University in the city of New York		
	FP9	WO 95/32305	11/30/1995	Dako A/S		
	FP10	W096/11266	04/18/1996	Amgen Inc.		
	FP11	WO 96/14875	05/23/1996	The Regents of the University of California		
	FP12	W096/32966	10/24/1996	Thomas Jefferson University		
	FP13	EP 0 747 706	12/11/1996	Gen-Probe Inc.		
	FP14	WO 98/02582	01/22/1998	Gen-Probe Inc.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	3	of	4	Attorney Docket Number	1619.0080002/JAG/CMB

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>5</sup>	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if Known)			
	US41	6,395,278	05/28/2002	Xu et al.	
	US42	6,465,611	10/15/2002	Xu et al.	
	US43	6,479,263	11/12/2002	Slawin et al.	
	US44	6,528,260	03/04/2003	Blumenfeld et al.	
	US45	6,534,273	03/18/2003	Weisburg et al.	
	US46	6,551,778	12/22/2003	Harvey et al.	
	US47	6,800,746	10/05/2004	Xu et al.	
	US48	6,897,024	05/24/2005	Bussemakers et al.	
	US49	7,008,765	03/07/2006	Bussemakers et al.	
	US50	7,138,235	11/21/2006	Bussemakers et al.	
	US51	7,368,545	05/06/2008	Busse et al.	
	US52	2002/0022248 A1	02/21/2002	Xu et al.	
	US53	2002/0035244 A1	03/21/2002	Cohen et al.	
	US54	2005/0158792 A1	03/22/2005	Bussemakers et al.	
	US55	2005/0164223 A1	07/28/2005	Schalken et al.	
	US56	2005/0282170 A1	12/22/2005	Fradet et al.	
	US57	2006/0099658 A1	05/11/2006	Bussemakers et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>5</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	FP15	WO 98/45420	10/15/1998	Diagnocure Inc.		
	FP16	WO 00/04149	01/27/2000	Corixa Corp.		
	FP17	WO 00/50899	08/31/2000	Artic Partners OY AB		
	FP18	WO 00/58470	10/05/2000	Srikantan, et al.		
	FP19	WO 01/23550	04/05/2001	Diagnocure Inc.		
	FP20	WO 01/25272	04/12/2001	Corixa Corp.		
	FP21	WO 01/25273	04/12/2001	Corixa Corp.		
	FP22	WO 01/34802	05/17/2001	Corixa Corp.		
	FP23	WO 01/44507	06/21/2001	Bio Merieux		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
*(Use as many sheets as necessary)*

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Equivalent of Form PTO/SB/08b (01-08)

Approved for use through 05/31/2008

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	12/098,577
Filing Date	April 7, 2008
First Named Inventor	BUSSE, Ursula
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	1619.0080002/JAG/CMB

Sheet 1 of 9

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	NPL1	Altschul, S.F., <i>et al.</i> , "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucl. Acids Res.</i> 25:3389-3402, Oxford University Press (1997)	
	NPL2	Arnold, Jr., L.J., <i>et al.</i> , "Assay Formats Involving Acridinium-Ester-Labeled DNA Probes," <i>Clin. Chem.</i> 35:1588-1594, American Association For Clinical Chemistry (1989)	
	NPL3	Black, D.L., "Mechanisms of Alternative Pre-Messenger RNA Splicing," <i>Annu. Rev. Biochem.</i> 72:291-336 (February 2003)	
	NPL4	Boom, R., <i>et al.</i> , "Rapid and Simple Method for Purification of Nucleic Acids," <i>J. Clin. Microbiol.</i> 28:495-503, American Society for Microbiology (1990)	
	NPL5	Boulikas, T., "Gene Therapy of Prostate Cancer: p53, Suicidal Genes, and Other Targets," <i>Anticancer Res.</i> 17:1471-1505, International Institute of Anticancer Research (1997)	
	NPL6	Bowie, J.U., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <i>Science</i> 247:1306-1311, American Association for the Advancement of Science (1990)	
	NPL7	Brakebusch, C., <i>et al.</i> , "Expression of the 90K Immunostimulator Gene Is Controlled by a Promoter with Unique Features," <i>J. Biol. Chem.</i> 272:3674-3682, The American Society for Biochemistry and Molecular Biology, Inc. (1997)	
	NPL8	Brown, A.M., "A step-by-step guide to non-linear regression analysis of experimental data using a Microsoft Excel spreadsheet," <i>Comput. Methods Programs Biomed.</i> 65:191-200, Elsevier Scientific Publishers (June 2001)	
	NPL9	Buck, G.A., <i>et al.</i> , "Design Strategies and Performance of Custom DNA Sequencing Primers," <i>BioTechniques</i> 27:528-536, Informa Healthcare USA, Inc. (September 1999)	
	NPL10	Burgess, W.H., <i>et al.</i> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>J. Cell. Biol.</i> 111:2129-2138, The Rockefeller University Press (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	2	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL11	Bussemakers, M.J., and Isaacs, W.B., "Identification of Genes Associated with Prostate Cancer Development," <i>Urol. Res. 21:452</i> , Abstract No. P42, Springer International (1993)	
	NPL12	Bussemakers, M.J.G., and Isaacs, W.B., "Identification of Genes Associated with Prostate Cancer Development," Presented at <i>8th Annual Spring Meeting, May 13 - May 14, San Fransico, CA</i> , one page, Society for Basic Urologic Research (1994)	
	NPL13	Bussemakers, M.J.G., <i>et al.</i> , "Identification of DD3: A New Gene Overexpressed in Prostatic Tumors," <i>Urol. Res. 23:253</i> , Abstract No. 0 36, Springer International (1995)	
	NPL14	Bussemakers, M.J.G., <i>et al.</i> , "DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors," Presented at <i>Fall Symposium, December 7 - 10, Chapel Hill, North Carolina</i> , 1 page, Society for Basic Urologic Research (1995)	
	NPL15	Bussemakers, M.J. G., <i>et al.</i> , "DD3: a new prostate specific marker, overexpressed in prostatic tumors," <i>Proc. Annu. Meet. Amer. Assoc. Cancer Res. 87:515</i> , Abstract No. 3522, American Association for Cancer Research (1996) .	
	NPL16	Bussemakers, M.J.G., <i>et al.</i> , "DD3: a new prostate specific marker, overexpressed in prostatic tumors," Presented at the <i>87<sup>th</sup> Annual Meeting of the American Association for Cancer Research, Washington, DC</i> , Abstract No. 3522, 1 page (1996)	
	NPL17	Bussemakers, M.J.G., <i>et al.</i> , "DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors," Presented at <i>Breast and Prostate Cancer: Basic Mechanisms, Taos, New Mexcio</i> , Abstract No. 102, 1 page (January 29 - February 4 1996)	
	NPL18	Bussemakers, M.J.G., <i>et al.</i> , "DD3: A New Prostate Specific Marker, Overexpressed in Prostatic Tumors," Presented at <i>Meeting for the Dutch Association for Tumor Cell Biology, May, The Netherlands</i> , 1 page (1996)	
	NPL19	Bussemakers, M.J.G., <i>et al.</i> , "DD3: A New Prostate-Specific Marker, Strongly Overexpressed in Prostatic Tumors," <i>Urol. Res. 25:76</i> , Abstract No. 02.2, Springer International (1997)	
	NPL20	Bussemakers, M.J.G., "Changes in Gene Expression and Targets for Therapy," <i>Eur. Urol. 35:408-412</i> , Elsevier Science (January 1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	3	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL21	Bussemakers, M.J.G., <i>et al.</i> , "Assessment of the Clinical Usefulness of the Prostate-Cancer-Specific DD3 Gene," <i>Eur. Urol.</i> 36: 508, Abstract No. 0139, Elsevier Science (November 1999)	
	NPL22	Bussemakers, M.J.G., <i>et al.</i> , "DD3: A New Prostate-Specific Gene, Highly Overexpressed in Prostate Cancer," <i>Cancer Res.</i> 59:5975-5979, American Association for Cancer Research (December 1999)	
	NPL23	Cairns, P., <i>et al.</i> , "Molecular Detection of Prostate Cancer in Urine by GSTP1 Hypermethylation," <i>Clin. Cancer Res.</i> 7:2727-2730, The American Association for Cancer Research (September 2001)	
	NPL24	Cheung, R.C., <i>et al.</i> , "Rapid and Sensitive Method for Detection of Hepatitis C Virus RNA by Using Silica Particles," <i>J. Clin. Microbiol.</i> 10:2593-2597, American Society for Microbiology (1994)	
	NPL25	Clements, J.A., <i>et al.</i> , "Molecular Detection of Prostate Cells in Ejaculate and Urethral Washings in Men With Suspected Prostate Cancer," <i>J. Urol.</i> 161:1337-1343, Lippincott Williams & Wilkins (April 1999)	
	NPL26	Cleutjens, K.B.J.M., <i>et al.</i> , "An Androgen Response Element in a Far Upstream Enhancer Region Is Essential for High, Androgen-Regulated Activity of the Prostate-Specific Antigen Promoter," <i>Mol. Endocrinol.</i> 11:148-161, The Endocrine Society (1997)	
	NPL27	Cleutjens, K.B.J.M., <i>et al.</i> , "A 6-kb Promoter Fragment Mimics in Transgenic Mice the Prostate-Specific and Androgen-Regulated Expression of the Endogenous Prostate-Specific Antigen Gene in Humans," <i>Mol. Endocrinol.</i> 11:1256-1265, The Endocrine Society (1997)	
	NPL28	de Kok, J.B., <i>et al.</i> , "DD3 <sup>PCA3</sup> , A Very Sensitive and Specific Marker to Detect Prostate Tumors," <i>Cancer Res.</i> 62:2695-2698, American Association for Cancer Research (May 2002)	
	NPL29	Edery, I., <i>et al.</i> , "High-level synthesis in <i>Escherichia coli</i> of functional cap-binding eukaryotic initiation factor eIF-4E and affinity purification using a simplified cap-analog resin," <i>Gene</i> 74:517-525, Elsevier/North-Holland (1988)	
	NPL30	Fradet, Y., <i>et al.</i> , "uPM3, A New Molecular Urine Test for the Detection of Prostate Cancer," <i>Urology</i> 64: 311-316, Elsevier Science Ltd. (August 2004)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	4	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL31	Freidmann, T., "Overcoming the Obstacles to Gene Therapy," <i>Sci. Am.</i> 276:96-101, Scientific American (1997)	
	NPL32	Gandini, O., <i>et al.</i> , "Is DD3 a New Prostate-Specific Gene?," <i>Anticancer Res.</i> 23:305-308, Anticancer Research (January-February 2003)	
	NPL33	Goessl, C., <i>et al.</i> , "A DNA-Based Method For Detection Of Prostate Cancer Cells In Urine After Prostatic Massage," <i>Eur. Urol. Suppl.</i> 1:32, article 118, Elsevier Science (January 2002)	
	NPL34	Goessl, C., <i>et al.</i> , "DNA-Based Detection Of Prostate Cancer In Urine After Prostatic Massage," <i>Urology</i> 58:335-338, Elsevier Science (September 2001)	
	NPL35	Goessl, C., <i>et al.</i> , "Fluorescent Methylation-specific Polymerase Chain Reaction for DNA-based Detection of Prostate Cancer in Bodily Fluids," <i>Cancer Res.</i> 60:5941-5945, American Association for Cancer Research (November 2000)	
	NPL36	Gotoh, A., <i>et al.</i> , "Development Of Prostate-Specific Antigen Promoter-Based Gene Therapy For Androgen-Independent Human Prostate Cancer," <i>J. Urol.</i> 160:220-229, American Urological Association, Inc. (July 1998)	
	NPL37	Guichet, A., <i>et al.</i> , "The nuclear receptor homologue Ftz-F1 and the homeodomain protein Ftz are mutually dependent cofactors," <i>Nature</i> 385:548-552, Nature Publishing Group (1997)	
	NPL38	Hessels, D., <i>et al.</i> , "DD3 <sup>PCA3</sup> -based Molecular Urine Analysis for the Diagnosis of Prostate Cancer," <i>Eur. Urol.</i> 44:8-15, Elsevier Science (July 2003)	
	NPL39	Houdebine, L-M., "Production of pharmaceutical proteins from transgenic animals," <i>J. Biochem.</i> 34:269-287, Oxford University Press (1994)	
	NPL40	Hsing, A.W., <i>et al.</i> , "International Trends And Patterns Of Prostate Cancer Incidence And Mortality," <i>Int. J. Cancer</i> 85:60-67, Wiley-Liss, Inc., (January 2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	5	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL41	Ingelfinger, R.J., "Nephrogenic Adenomas As Renal Tubular Outposts," <i>N. Engl. J. Med.</i> 347:684-686, Massachusetts Medical Society (August 2002)	
	NPL42	Iwakiri, J., <i>et al.</i> , "An Analysis Of Urinary Prostate Specific Antigen Before And After Radical Prostatectomy: Evidence for Secretion of Prostate Specific Antigen by the Periurethral Glands," <i>J. Urol.</i> 149:783-786, Elsevier Science Ltd. (1993)	
	NPL43	Kwoh, D.Y., <i>et al.</i> , "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 86:1173-1177, National Academy of Sciences (1989)	
	NPL44	Landis, S.H., <i>et al.</i> , "Cancer Statistics, 1999," <i>CA Cancer J. Clin.</i> 49:8-31, Lippincott Williams & Wilkins (January-February 1999)	
	NPL45	Lathe, R., "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data Theoretical and Practical Considerations," <i>J. Mol. Biol.</i> 183:1-12, Academic Press (1985).	
	NPL46	Lazar, E., <i>et al.</i> , "Transforming growth factor $\alpha$ : mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Mol. Cell Biol.</i> 8:1247-1252, American Society for Microbiology (1988)	
	NPL47	Lizardi, P., <i>et al.</i> , "Exponential Amplification Of Recombinant-RNA Hybridization Probes," <i>BioTechnology</i> 6:1197-1202, Nature Publishing Group (1988)	
	NPL48	Malek, L., <i>et al.</i> , "Nucleic Acid Sequence-Based Amplification (NASBA)," <i>Methods Mol. Biol.</i> 28:253-260, Humana Press (1994)	
	NPL49	Martiniello-Wilks, R., <i>et al.</i> , "In Vivo Gene Therapy for Prostate Cancer: Preclinical Evaluation of Two Different Enzyme-Directed Prodrug Therapy Systems Delivered by Identical Adenovirus Vectors," <i>Hum. Gene Ther.</i> 9:1617-1626, Mary Ann Liebert, Inc. (July 1998)	
	NPL50	Matteucci, M.D., and Caruthers, M.H., "Synthesis of Deoxyoligonucleotides on a Polymer Support," <i>J. Am. Chem. Soc.</i> 103:3185-3191, American Chemical Society (1981)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	6	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL51	Merriam-Webster Online Dictionary, definition for "kit" (Accessed December 2005)	
	NPL52	Miller, P.S., and Ts'o, P.O.P., "Chapter 30: Oligonucleotide Inhibitors of Gene Expression in Living Cells: New Opportunities in Drug Design," <i>Annu. Rep. Med. Chem.</i> 23:295-304, Academic Press (1988)	
	NPL53	Millikan, R.E., "Chemotherapy of Advanced Prostatic Carcinoma," <i>Semin. Oncol.</i> 26:185-191, W.B. Saunders Company (April 1999)	
	NPL54	Morvan, F., <i>et al.</i> , "α-DNA. I. Synthesis, characterization by high field <sup>1</sup> H-NMR, and base-pairing properties of the unnatural hexadeoxyribonucleotide α-[d(CpCpTpTpCpC)] with its complement β-[d(GpGpApApGpG)]," <i>Nucleic Acids Res.</i> 14:5019-5035, Oxford University Press (1986)	
	NPL55	Pang, S., <i>et al.</i> , "Identification of a Positive Regulatory Element Responsible for Tissue-specific Expression of Prostate-specific Antigen," <i>Cancer Res.</i> 57:495-499, The American Association for Cancer Research (1997)	
	NPL56	Quandt, K., <i>et al.</i> , "MatInd and MatInspector: new, fast and versatile tools for detection of consensus matches in nucleotide sequence data," <i>Nucl. Acids Res.</i> 23:4878-4884, Oxford University Press (1995)	
	NPL57	Rieger-Christ, K., <i>et al.</i> , "Identification of Fibroblast Growth Factor Receptor 3 Mutations in Urine Sediment DNA Samples Complements Cytology in Bladder Tumor Detection," <i>Cancer</i> 98:737-744, American Cancer Society (August 2003)	
	NPL58	Ringsrud, K.M., "Cells in the Urine Sediment," <i>Lab. Med.</i> 32:153-155, American Society for Clinical Pathology (March 2001)	
	NPL59	Rubanyi, G.M., "The future of human gene therapy," <i>Mol. Aspects Med.</i> 22:113-142, Elsevier Science (June 2001)	
	NPL60	Schalken, J., "Molecular Diagnostics and Therapy of Prostate Cancer: New Avenues," <i>Eur. Urol. 34 Suppl</i> 3:3-6, S. Karger AG (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	7	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL61	Schuur, E.R., <i>et al.</i> , "Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer," <i>J. Biol. Chem.</i> 271:7043-7051, The American Society for Biochemistry and Molecular Biology, Inc. (1996)	
	NPL62	Schwartz, C.J., <i>et al.</i> , "FTZ-Factor1 and Fushi tarazu interact via conserved nuclear receptor and coactivator motifs," <i>EMBO J.</i> 20:510-519, Oxford University Press (February 2001)	
	NPL63	Strickler, H.D., and International SV40 Working Group, "A Multicenter Evaluation of Assays for Detection of SV40 DNA and Results in Masked Mesothelioma Specimens," <i>Cancer Epidemiol. Biomarkers Prev.</i> 10:523-532, American Association for Cancer Research (May 2001)	
	NPL64	Tamimi, Y., <i>et al.</i> , "DiagnoGene PCA3 reliable NASBA based reagents for detecting PCA3 mRNA, a recently described prostate marker," <i>Proc. Am. Assoc. Cancer Res.</i> 39:234 Poster Abstract, Williams & Wilkins (March 1998),	
	NPL65	Taneja, S.S., <i>et al.</i> , "Chapter 23: Gene Therapy: Principles and Potential," in <i>Cancer Surveys: Preventing Prostate Cancer: Screening versus Chemoprevention</i> , Oliver, R.T.D., <i>et al.</i> , eds., Cold Spring Harbor Laboratory Press, pp. 247-266 (1995)	
	NPL66	Tockman, M.S., <i>et al.</i> , "Considerations in Bringing a Cancer Biomarker to Clinical Application," <i>Cancer Res.</i> 52:2711s-2718s, American Association for Cancer Research (1992)	
	NPL67	Tyagi, S., and Kramer, F.R., "Molecular Beacons: Probes that Fluoresce upon Hybridization," <i>Nat. Biotechnol.</i> 14:303-308, Nature Publishing Group (1996)	
	NPL68	Verhaegh, G.W., <i>et al.</i> , "Characterization of the Prostate-Cancer-Specific DD3 Gene Promoter," <i>Eur. Urol.</i> 38:490, Abstract 10, S. Karger (October 2000)	
	NPL69	Verhaegh, G.W., <i>et al.</i> , "Isolation and Characterization of the Promoter of the Human Prostate Cancer-specific DD3 Gene," <i>J. Biol. Chem.</i> 275:37496-37503, The American Society for Biochemistry and Molecular Biology (December 2000)	
	NPL70	Verma, I.M., and Somia, N., "Gene therapy - promises, problems and prospects," <i>Nature</i> 389:239-242, Nature Publishing Group (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	8	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL71	Voet, D., and Voet, J.G., eds., "Chapter 28: Nucleic Acid Structures and Manipulation," in <i>Biochemistry, 1st Ed.</i> , John Wiley & Sons, Inc., San Francisco, CA, pp. 893-900 (1990)	
	NPL72	Walker, G.T., <i>et al.</i> , "Isothermal <i>in vitro</i> amplification of DNA by a restriction enzyme/DNA polymerase system," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 89:392-396, National Academy of Sciences (1992)	
	NPL73	Walker, G.T., <i>et al.</i> , "Strand displacement amplification--an isothermal, <i>in vitro</i> DNA amplification technique," <i>Nucleic Acids Res.</i> 20:1691-1696, Oxford University Press (1992)	
	NPL74	Wei, C., <i>et al.</i> , "Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy," <i>Proc. Natl. Acad. Sci. USA</i> 94:6369-6374, The National Academy of Sciences of the USA (1997)	
	NPL75	Weiss, R., "Hot Prospect for New Gene Amplifier," <i>Science</i> 254:1292-1293, American Association for the Advancement of Science (1991)	
	NPL76	Yelin, R., <i>et al.</i> , "Widespread occurrence of antisense transcription in the human genome," <i>Nat. Biotechnol.</i> 21:379-386, Nature Publishing Group (April 2003)	
	NPL77	Database EMBL Online, Accession No. AF103908 (November 1999).	
	NPL78	DATABASE NCBI, Accession No. AF103907 (August 2000)	
	NPL79	DATABASE NCBI, Accession No. AF103908 (August 2000)	
	NPL80	NCBI Entrez, GenBank Report, Accession No. AL359314 (May 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	12/098,577
				Filing Date	April 7, 2008
				First Named Inventor	BUSSE, Ursula
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	9	of	9	Attorney Docket Number	1619.0080002/JAG/CMB

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T <sup>2</sup>
	NPL81	Office Action for United States Patent Application No. 09/996,953, inventors Bussemakers, M.J., <i>et al.</i> , filed November 30, 2001, mailed on August 26, 2003	
	NPL82	Sequence Comparisons in Office Action for United States Patent Application No. 10/773,440, inventors Fradet, Y. <i>et al.</i> , filed February 9, 2004, mailed on June 23, 2006	
	NPL83	Co-pending U.S. Application No. 11/794,048, filed on December 23, 2005 (NOT YET PUBLISHED)	

847818\_1.doc

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.